Chapter 14: Blood

General Characteristics and Physical Properties of Blood

• Classification: Blood is classified as the human body's only liquid connective tissue, characterized by cellular components suspended within a fluid extracellular matrix known as plasma.

• Primary Physiological Functions:

  • Transport: Carries vital substances including oxygen, carbon dioxide, metabolic nutrients, waste products, vitamins, and hormones throughout the body.

  • Homeostasis Regulation: Regulates physiological processes, including fluid volume, systemic acid-base equilibrium, and electrolyte concentration.

  • Interstitial Stability: Maintains the dynamic equilibrium and volume stability of interstitial fluids surrounding tissues.

  • Thermal Regulation: Absorbs and redistributes metabolic heat from deep tissues to peripheral vascular beds.

• Physical Properties and Systemic Parameters:

  • Systemic pH Range: Strictly regulated within a normal physiological range of $7.3\text{--}7.5$.

  • Proportion of Body Weight: Accounts for approximately $8\%$ of total body mass.

  • Adult Blood Volume:

  • Adult Females: Approximately $4\text{--}5\,\text{liters}$.

  • Adult Males: Approximately $5\text{--}6\,\text{liters}$.

  • Volume Variations: Total volume fluctuates depending on body dimensions, total adipose tissue volume, and shifts in systemic water and electrolyte balance.

• Formed Elements: Cellular fragments and cells produced primarily within red bone marrow:

  • Erythrocytes (Red Blood Cells / RBCs).

  • Leukocytes (White Blood Cells / WBCs).

  • Thrombocytes (Platelets / cell fragments).

Blood Composition and Centrifugation Fractions

• Diagnostic Centrifugation of Whole Blood: Centrifugation separates whole blood into three distinct layers based on cellular and molecular densities to detect underlying hematologic abnormalities:

  • Plasma (Supernatant):

  • Positioned at the top of the centrifuge tube.

  • Represents approximately $55\%$ of total blood volume.

  • Appears as a clear, straw-colored liquid matrix composed of $92\%$ water, $7\%$ plasma proteins, and $1\%$ dissolved solutes (electrolytes, metabolic wastes, nutrients, vitamins, hormones, and gases).

  • Buffy Coat (Intermediate Layer):

  • Thin, white-to-gray layer situated at the interface between plasma and packed erythrocytes.

  • Comprises less than $1\%$ of total blood volume.

  • Contains leukocytes (white blood cells) and thrombocytes (platelets).

  • Packed Red Blood Cells (Pellet):

  • Positioned at the bottom of the tube.

  • Represents the hematocrit (HCT), comprising approximately $45\%$ of whole blood volume.

  • Reference Hematocrit Ranges:

    • Adult Females: $35\%\text{--}46\%$.

    • Adult Males: $40\%\text{--}54\%$.

• Relative Distribution Among Formed Elements ($45\%$ of Total Blood):

  • Red Blood Cells: Account for $95.1\%$ of all formed elements.

  • Platelets: Account for $4.8\%$ of formed elements.

  • White Blood Cells: Account for $0.1\%$ of formed elements.

• Differential Leukocyte Proportions (Within Total Leukocyte Fraction):

  • Neutrophils: $50\%\text{--}70\%$ (alternatively cited as $54\%\text{--}70\%$).

  • Lymphocytes: $25\%\text{--}33\%$.

  • Monocytes: $3\%\text{--}9\%$.

  • Eosinophils: $1\%\text{--}3\%$ (or up to $4\%$).

  • Basophils: Less than $1\%$.

Clinical Universal Precautions and Bloodborne Pathogen Safety

• Definition and Core Principle: Universal precautions constitute a rigorous set of standardized infection-control protocols employed by healthcare professionals to prevent parenteral, mucous membrane, and non-intact skin exposure to bloodborne pathogens. The operating guideline assumes that blood and all body fluids from every patient are potentially infectious.

• Target Pathogens: Formulated principally to mitigate transmission risks of:

  • Human Immunodeficiency Virus (HIV).

  • Hepatitis B Virus (HBV).

  • Hepatitis C Virus (HCV).

• Epidemiological Risk: Unsafe healthcare injection practices account for an estimated $4\%\text{--}7\%$ of newly acquired systemic infectious diseases globally.

• Standardized Engineering and Work-Practice Controls:

  • Personal Protective Equipment (PPE): Mandatory routine deployment of barrier protections including medical-grade gloves, eye shields, gowns, and masks.

  • Engineering Controls: Mandatory utilization of biological safety fume hoods and puncture-resistant sharps disposal units.

  • Safe Workplace Habits: Immediate hand hygiene protocols before and after patient contact, coupled with safe needle handling (eliminating needle recapping).

Hematopoiesis and the Origin of Formed Elements

• Hematopoiesis (Hemopoiesis): The continuous process of blood cell production and maturation, occurring predominantly within the vascularized red bone marrow found in the trabecular spaces of the axial skeleton and proximal epiphyses of long bones.

• Pluripotent Hematopoietic Stem Cells (Hemocytoblasts):

  • Primitive stem cells capable of continuous self-renewal.

  • Capable of asymmetric division to yield committed, differentiated progenitor lineages when exposed to hematopoietic growth factors and colony-stimulating factors (CSFs).

• Divergent Lineage Pathways:

  • Myeloid Lineage:

  • Progenitor Myeloid Stem Cell gives rise to multiple distinct developmental precursor lines:

    • Erythroblasts: Proliferate and condense into Reticulocytes, which extrude their nuclei before entering circulation to mature into functional Erythrocytes.

    • Megakaryoblasts: Mature into giant polyploid Megakaryocytes, which undergo membrane demarcation and cytoplasmic shedding into sinusoidal capillaries to produce circulating Platelets.

    • Myeloblasts: Differentiate through promyelocyte and myelocyte stages to yield circulating Granulocytes (Neutrophils, Eosinophils, and Basophils).

    • Monoblasts: Mature through intermediate stages to generate circulating Monocytes, which extravasate into tissues to become active Macrophages.

  • Lymphoid Lineage:

  • Progenitor Lymphoid Stem Cell differentiates into Lymphoblasts, which further differentiate into T Lymphocytes and B Lymphocytes.

  • B lymphocytes exposed to antigens and costimulatory signals transition into antibody-secreting Plasma Cells within lymphoid tissues.

Erythrocytes (Red Blood Cells): Structure, Function, and Gas Transport

• Morphology and Physical Dimensions:

  • Anucleated biconcave discs characterized by thin central depressions and thickened outer rims.

  • Average Cell Diameter: $7.5\,\mu\text{m}$.

  • Maximum Rim Thickness: $2.0\,\mu\text{m}$.

  • Biomechanical Advantages:

  • Biconcave configuration significantly increases the surface-area-to-volume ratio, facilitating rapid diffusion of respiratory gases across the plasmalemma.

  • Enhances mechanical flexibility, allowing RBCs to deform reversibly when navigating microcapillaries narrower than their rest diameter.

• Organelle Composition and Metabolic Biochemistry:

  • Mature erythrocytes lack nuclei, ribosomes, and mitochondria, which maximizes internal volume for hemoglobin packing.

  • Inability to undergo mitotic division or synthesize structural proteins.

  • Generate ATP exclusively via anaerobic glycolysis, avoiding consumption of the oxygen molecules bound for peripheral tissue delivery.

• Hemoglobin Dynamics:

  • Hemoglobin makes up approximately one-third of total erythrocyte volume.

  • Quaternary Structure: Tetrameric metalloprotein consisting of four globin polypeptide subunits (two alpha chains and two beta chains), each complexed with an iron-bearing protoporphyrin ring known as a heme group.

  • Chemical States:

  • Oxyhemoglobin: Hemoglobin saturated with molecular oxygen ($\text{O}_2$); exhibits a bright red color.

  • Deoxyhemoglobin: Hemoglobin from which oxygen has dissociated; exhibits a dark red/purple color that appears bluish through venous walls.

• Reference Red Blood Cell Counts: Quantified as the absolute count of erythrocytes per cubic millimeter ($\text{mm}^3$) or microliter ($\mu\text{L}$) of whole blood:

  • Adult Males: $4{,}700{,}000\text{--}6{,}100{,}000\,\mu\text{L}^{-1}$.

  • Adult Females: $4{,}200{,}000\text{--}5{,}400{,}000\,\mu\text{L}^{-1}$.

  • Children: $4{,}500{,}000\text{--}5{,}100{,}000\,\mu\text{L}^{-1}$.

  • Clinical alterations in circulating RBC count correspond to alterations in oxygen delivery and hematocrit.

Erythrocyte Life Cycle, Erythropoiesis, and Nutritional Requirements

• Erythropoiesis Regulation via Negative Feedback:

  • Primary Regulatory Hormone: Erythropoietin (EPO), a glycoprotein hormone secreted predominantly by specialized interstitial peritubular cells in the kidneys ($\approx 90\%$) and secondarily by hepatocytes in the liver ($\approx 10\%$).

  • Stimulus: Hypoxemia or decreased partial pressure of oxygen ($\text{pO}_2$) in circulating blood triggered by high altitudes, pulmonary insufficiency, blood loss, or excessive aerobic demand.

  • Physiological Cascade:

  • Renal and hepatic sensor cells detect hypoxia and elevate EPO secretion into systemic circulation.

  • EPO stimulates committed myeloid erythroblast precursors in red bone marrow to accelerate mitotic division, hemoglobin synthesis, and reticulocyte maturation.

  • Circulating RBC mass expands, restoring blood oxygen-carrying capacity.

  • Elevated systemic oxygen delivery provides negative feedback inhibition to renal and hepatic tissue, down-regulating EPO transcription.

• Essential Dietary Factors for Erythropoiesis:

  • Vitamin $\text{B}_{12}$ (Cobalamin):

  • Source: Ingested via diet, absorbed in the distal ileum of the small intestine via receptor-mediated endocytosis.

  • Absorption Requirement: Strictly dependent on complexing with intrinsic factor, a protective glycoprotein secreted by gastric mucosal parietal cells.

  • Function: Serves as a cofactor in nucleotide synthesis; essential for nuclear maturation, normal DNA replication, and mitotic division in hematopoietic cell lines.

  • Folic Acid (Vitamin $\text{B}_9$):

  • Source: Absorbed directly through the mucosal brush border of the small intestine.

  • Function: Precursor in thymidine synthesis required for genomic DNA synthesis, cell growth, and regular erythroblast mitotic division.

  • Iron ($\text{Fe}^{2+}/\text{Fe}^{3+}$):

  • Source: Dietary absorption along the proximal duodenum of the small intestine; supplemented by salvage pathways that recover endogenous iron from senescent RBC degradation.

  • Function: Incorporated into the central coordination site of protoporphyrin rings during heme and hemoglobin synthesis.

Pathologies of Erythrocytes and Clinical Anemias

• General Pathology: Anemia is characterized by a significant reduction in systemic oxygen-carrying capacity, caused by deficient circulating RBC numbers, low total hemoglobin concentration, or structural hemoglobin defects.

• Etiological Classification of Anemias:

Destruction of Red Blood Cells and Hemoglobin Catabolism

• Erythrocyte Senescence: Over an average functional lifespan of $120\,\text{days}$, RBCs travel roughly $700\,\text{miles}$ through the vascular tree. Repeated mechanical compression through narrow capillary beds damages plasma membrane proteins, depleting enzymatic reserves and causing membrane lipid peroxidation and loss of deformability.

• Phagocytosis and Reticuloendothelial Clearance: Stiffened, fragile erythrocytes fragment within tortuous venous sinuses of the spleen and liver, where resident fixed tissue macrophages (Kupffer cells in the liver and splenic macrophages) engulf and digest them.

• Step-by-Step Pathway of Hemoglobin Catabolism:

  1. Capillary Shearing: Mechanical passage through tight microvascular beds shears aged, non-deformable erythrocytes.

  2. Phagocytosis: Spleen and liver reticuloendothelial macrophages engulf damaged RBC fragments.

  3. Dissociation: Hemoglobin is cleaved into its constituent parts: globin polypeptide chains and iron-protoporphyrin heme groups.

  4. Heme Cleavage: Heme oxygenase cleaves the heme porphyrin ring, releasing free elemental iron and converting the organic tetrapyrrole backbone into green biliverdin.

  5. Iron Conservation:

  • Released iron binds to the transport protein transferrin in the plasma, which returns it to the red bone marrow for de novo erythropoiesis.

  • Excess intracellular iron complexes with apoferritin to form stable storage aggregates known as ferritin in the liver and spleen.

  1. Bilirubin Conversion: Biliverdin reductase reduces biliverdin into the yellow-orange pigment bilirubin.

  2. Biliary Excretion: Macrophages release bilirubin into the blood; it binds albumin, travels to hepatocytes, undergoes glucuronide conjugation, and is secreted into bile.

  3. Globin Degradation: Macrophages hydrolyze globin chains into free amino acids, releasing them into the circulating plasma pool for protein resynthesis.

  4. Renal Excretion of Bilirubin Derivatives: Intestinal bacteria further metabolize excreted bile pigments, and some water-soluble breakdown derivatives re-enter the blood to be cleared by the kidneys and excreted in urine.

Leukocytes (White Blood Cells): Classification, Defense Mechanisms, and Counts

• Physiological Role and Turnover: Leukocytes (WBCs) provide immune defense against pathogenic microorganisms, parasites, virally transformed cells, and toxic debris. They function mainly in the peripheral tissues and have variable, finite lifespans, requiring continuous myeloid and lymphoid renewal.

• General Defensive Behaviors:

  • Diapedesis: Active process where leukocytes squeeze between adjacent endothelial cells in post-capillary venules to exit the bloodstream and enter connective tissue stroma.

  • Cellular Adhesion Molecules (CAMs): Endothelial selectins and leukocyte integrins guide and slow circulating WBCs (rolling adhesion) before transendothelial extravasation.

  • Positive Chemotaxis: Directed migration along a chemical concentration gradient formed by bacterial metabolites, kinins, or cytokines released by inflamed or injured tissues.

  • Phagocytosis: Receptor-mediated endocytosis and lysosomal enzymatic degradation of particulate foreign antigens, bacteria, and necrotic debris; carried out primarily by neutrophils and monocytes.

  • Inflammatory Amplification: Localized defense cascade characterized by vasodilation, elevated capillary permeability, plasma extravasation (edema), and selective recruitment of granulocytes.

• Quantitative Leukocyte Diagnostics:

  • Standard White Blood Cell Count (WBC Count): $3{,}500\text{--}10{,}500\,\mu\text{L}^{-1}$ (or $\text{mm}^{-3}$) of circulating blood.

  • Leukocytosis: Circulating count exceeding $10{,}500\,\mu\text{L}^{-1}$; typically indicates acute bacterial infection, physical trauma, intense physical exercise, or severe metabolic dehydration.

  • Leukopenia: Circulating count falling below $3{,}500\,\mu\text{L}^{-1}$; points to pathologies such as typhoid fever, influenza, measles, mumps, varicella (chickenpox), poliomyelitis, advanced AIDS, or aplastic bone marrow failure.

  • Differential White Blood Cell Count: Quantifies the relative percentages of each leukocyte subtype within a peripheral blood sample. Shifts in these proportions aid in differential diagnosis:

  • Marked neutrophilia indicates acute pyogenic bacterial invasion.

  • Depletion of circulating helper T-lymphocytes ($\text{CD4}^+$ T cells) is a hallmark of progressive HIV infection.

Characteristics of Leukocyte Subtypes: Granulocytes and Agranulocytes

Granulocytes

Leukocytes with prominent membrane-bound secretory granules within their cytoplasm, polymorphic nuclei, and short lifespans (typically hours to a few days). They are approximately twice the diameter of circulating red blood cells.

• Neutrophils (Polymorphonuclear Leukocytes / PMNs):

  • Relative Proportion: $50\%\text{--}70\%$ of circulating leukocytes.

  • Nuclear Architecture: Segmented, variable nucleus containing $2\text{--}5$ interconnected lobes.

  • Granule Staining: Fine, neutral-staining cytoplasmic granules that turn light purple/lilac under combined Wright's or Giemsa acid-base staining protocols.

  • Physiological Role: Primary cellular responders to acute bacterial infection and tissue necrosis; undergo positive chemotaxis and actively phagocytize opsonized micro-pathogens.

• Eosinophils:

  • Relative Proportion: $1\%\text{--}3\%$ (or up to $4\%$) of circulating leukocytes.

  • Nuclear Architecture: Distinct bilobed nucleus.

  • Granule Staining: Coarse, uniformly round cytoplasmic granules that stain deep red/crimson with acidic dyes such as eosin.

  • Physiological Role: Degranulate cytotoxic enzymes to destroy multicellular parasitic helminths (worms); release histaminase to moderate systemic allergic reactions.

• Basophils:

  • Relative Proportion: Less than $1\%$ of circulating leukocytes.

  • Nuclear Architecture: Irregularly lobed nucleus, often obscured by overlying granules.

  • Granule Staining: Coarse, variable cytoplasmic granules that stain deep blue/purple with basic dyes such as methylene blue.

  • Physiological Role: Structurally homologous to tissue mast cells; release histamine (a potent vasodilator that increases microvascular permeability) and heparin (a sulfated polysaccharide anticoagulant that inhibits local thrombin activity).

Agranulocytes

Leukocytes that lack prominent, visible cytoplasmic granules under light microscopy and possess non-fragmented nuclei.

• Monocytes:

  • Relative Proportion: $3\%\text{--}9\%$ of circulating leukocytes.

  • Physical Size: Largest leukocyte subtype, roughly two to three times the diameter of a standard erythrocyte.

  • Nuclear Architecture: Large nucleus with variable morphology: oval, indented, spherical, or deeply kidney-shaped (reniform).

  • Physiological Role: Circulate transiently for a few days before extravasating into tissue parenchyma, where they differentiate into voracious, long-lived macrophages (surviving for weeks or months) capable of engulfing large particulate debris, dead cells, and resistant intracellular bacteria.

• Lymphocytes:

  • Relative Proportion: $25\%\text{--}33\%$ of circulating leukocytes.

  • Physical Size: Smallest leukocytes, only slightly larger than normal erythrocytes.

  • Nuclear Architecture: Massive, deeply staining spherical nucleus surrounded by a narrow rim of light blue cytoplasm.

  • Physiological Role: Key mediators of acquired (adaptive) immune responses; can survive for years or decades as memory lines.

  • T Lymphocytes (T Cells): Mature in the thymus; directly destroy foreign pathogens, graft tissues, and virally infected or malignant host cells via cytotoxic perforin/granzyme pathways.

  • B Lymphocytes (B Cells): Mature in bone marrow; differentiate into plasma cells that synthesize and secrete antigen-specific immunoglobulins (antibodies).

Blood Platelets (Thrombocytes) and Megakaryocytopoiesis

• Origin and Maturation:

  • Platelets are non-nucleated fragments shed from giant megakaryocytes in red bone marrow.

  • Developmental Pathway: Hematopoietic Stem Cell (Hemocytoblast) $\rightarrow$ Megakaryoblast $\rightarrow$ Megakaryocyte $\rightarrow$ Platelet shedding.

  • Primary Regulatory Factor: Thrombopoietin (TPO), a glycoprotein produced by the liver and kidneys that stimulates megakaryocyte polyploidization and fragmentation.

• Structure and Reference Values:

  • Discoid fragments measuring less than half the diameter of a red blood cell ($\approx 2\text{--}4\,\mu\text{m}$).

  • Normal Reference Range: $150{,}000\text{--}400{,}000\,\mu\text{L}^{-1}$.

  • Thrombocytosis: Pathological elevation of circulating platelets above normal limits, increasing the risk of spontaneous thrombosis.

  • Thrombocytopenia: Platelet count below normal limits; leads to microvascular purpura, petechiae, and extended bleeding times.

• Primary Functions in Hemostasis:

  • Adhere to exposed subendothelial collagen fibers to form an initial mechanical seal (platelet plug).

  • Synthesize and release vasoconstrictive mediators, such as serotonin, which induce smooth muscle contraction in torn vessel walls.

  • Present a procoagulant phospholipid surface that coordinates clotting factor assembly during the coagulation cascade.

Blood Plasma: Composition, Solutes, and Plasma Proteins

• General Features: Liquid fraction of uncoagulated blood ($55\%$ of volume); composed of $92\%$ water, $7\%$ proteins, and a mixture of inorganic ions and organic metabolites. Functions in nutrient distribution, systemic waste transport, electrolyte balance, and osmotic buffering.

• Plasma Protein Classes and Functional Profiles:

Plasma Nutrients, Blood Gases, Nonprotein Nitrogenous Substances, and Electrolytes

• Dissolved Blood Gases:

  • Oxygen ($\text{O}_2$): Mostly bound to hemoglobin, with a minor fraction dissolved in plasma solution.

  • Carbon Dioxide ($\text{CO}_2$): Transported dissolved in solution, bound to amino residues as carbamino compounds, or converted to bicarbonate ions ($\text{HCO}_3^-$).

  • Nitrogen ($\text{N}_2$): Dissolved in plasma with no metabolic role.

• Plasma Nutrients:

  • Carbohydrates: Glucose absorbed from the alimentary canal or mobilized via hepatic glycogenolysis.

  • Amino Acids: Products of intestinal proteolysis and protein catabolism.

  • Nucleotides: Bases and nucleosides synthesized endogenously or salvaged from dietary breakdown.

  • Lipid Fractions: Insoluble dietary and endogenous lipids transported as specialized lipoprotein complexes:

  • Neutral fats (Triglycerides).

  • Phospholipids.

  • Free and esterified cholesterol.

• Nonprotein Nitrogenous Substances (NPNs):

  • Small organic molecules containing nitrogen that are not classified as proteins:

  • Urea: Chief product of amino acid deamination and hepatic urea cycle activity; constitutes approximately $50\%$ of all circulating NPNs.

  • Uric Acid: Product of purine nucleotide base catabolism.

  • Creatine: High-energy phosphate donor stored in skeletal muscle to regenerate ATP.

  • Creatinine: Invariant waste product formed by non-enzymatic breakdown of muscle creatine phosphate.

  • Diagnostic Application (Blood Urea Nitrogen / BUN): Measures the nitrogen fraction derived from urea. Elevated BUN levels indicate impaired glomerular filtration or renal insufficiency.

• Plasma Electrolytes:

  • Inorganic Cations and Anions: Essential for maintaining resting membrane potentials, action potentials, enzyme activation, and plasma osmolarity.

  • Constituents: Sodium ($\text{Na}^+$), Potassium ($\text{K}^+$), Calcium ($\text{Ca}^{2+}$), Magnesium ($\text{Mg}^{2+}$), Chloride ($\text{Cl}^-$), Bicarbonate ($\text{HCO}_3^-$), Phosphate ($\text{PO}_4^{3-}$), and Sulfate ($\text{SO}_4^{2-}$).

  • Dominant Species: Sodium ($\text{Na}^+$) and Chloride ($\text{Cl}^-$) are the most abundant extracellular electrolytes, largely determining plasma osmolarity.

Hemostasis: Vascular Spasm and Platelet Plug Formation

• Definition: Hemostasis is the sequence of physiological mechanisms that arrests blood loss from ruptured or severed blood vessels, operating most effectively within low-pressure microvascular networks.

• Three Major Mechanisms of Hemostasis:

  • Vascular Spasm.

  • Platelet Plug Formation.

  • Blood Coagulation (Fibrin Clot Formation).

• Mechanisms, Stimuli, and Physiological Effects:

Blood Coagulation: Extrinsic, Intrinsic, and Common Clotting Cascades

• Coagulation Overview: The primary and most effective hemostatic mechanism. It operates via an enzymatic amplification cascade where inactive zymogens are sequentially converted into active serine proteases, culminating in a stable fibrin clot within $5\text{--}15\,\text{minutes}$. Complete pathway functioning requires adequate dietary Vitamin K, which is an essential cofactor for hepatic post-translational gamma-carboxylation of factors II, VII, IX, and X.

• Extrinsic Clotting Mechanism (Tissue Factor Pathway):

  • Trigger: Traumatic injury to perivascular tissues or the vessel wall that allows blood to contact extravascular tissues.

  • Initiating Factor: Damaged cells release Tissue Thromboplastin (Factor III / Tissue Factor).

  • Enzymatic Cascade: Factor III complexes with Factor VII in the presence of Calcium ions ($\text{Ca}^{2+}$) to form an enzymatic complex that activates Factor X.

  • Feedback: Operates as a positive feedback mechanism; initial thrombin formation feeds back to accelerate upstream activation.

• Intrinsic Clotting Mechanism (Contact Activation Pathway):

  • Trigger: Initiates without external tissue trauma when blood contacts negatively charged foreign surfaces (such as glass in vitro) or exposed subendothelial collagen fibers in vivo.

  • Initiating Factor: Activation of Hageman Factor (Factor XII).

  • Enzymatic Cascade: Active Factor XII activates Factor XI, which subsequently activates Factor IX. Active Factor IX then associates with Factor VIII, platelet phospholipids, and Calcium ions ($\text{Ca}^{2+}$) to activate Factor X.

• The Common Clotting Pathway:

  • Convergence Point: Both pathways converge at the activation of Factor X.

  • Prothrombin Activator Complex: Active Factor X combines with Factor V, platelet phospholipids, and $\text{Ca}^{2+}$ to form the Prothrombin Activator complex.

  • Thrombin Generation: Prothrombin activator cleaves Prothrombin (Factor II) into the active serine protease Thrombin (Factor IIa).

  • Fibrin Polymerization: Thrombin cleaves low-molecular-weight fibrinopeptides from soluble Fibrinogen (Factor I), generating insoluble fibrin monomers that polymerize into long, sticky threads.

  • Clot Stabilization: Thrombin activates Factor XIII (Fibrin Stabilizing Factor), which catalyzes covalent cross-linking between adjacent fibrin strands in the presence of $\text{Ca}^{2+}$, trapping erythrocytes and platelets into a stable hemostatic plug.

  • Feedback Amplification: Thrombin reinforces prothrombin activator assembly by directly activating Factor V.

Clot Retraction, Repair, Fibrinolysis, and Prevention of Coagulation

• Clot Retraction and Serum Squeezing:

  • Following formation, platelet pseudopods containing actin and myosin filaments contract, pulling the meshwork inward.

  • This process draws the ruptured edges of the injured vessel together.

  • Expresses serum from the clot mass. (Serum is defined as plasma minus fibrinogen and consumed clotting factors).

• Vascular Tissue Remodeling: Platelets trapped within the thrombus release Platelet-Derived Growth Factor (PDGF), a cytokine that stimulates mitosis in vascular smooth muscle cells and perivascular fibroblasts to reconstruct the damaged vessel wall.

• Fibrinolysis (Clot Dissolution):

  • As healing progresses, inactive plasma plasminogen is converted into the active proteolytic enzyme plasmin by tissue plasminogen activator (tPA) or urokinase.

  • Plasmin digests insoluble fibrin polymers into soluble degradation fragments, dissolving the mature clot and restoring luminal patency.

• Endogenous Mechanisms Preventing Inappropriate Coagulation:

  • Endothelial Smoothness: Intact, non-disrupted vascular endothelium presents a smooth, non-thrombogenic surface that prevents the contact activation of Factor XII and mechanical platelet adhesion.

  • Prostacyclin ($\text{PGI}_2$): Prostaglandin continuously synthesized and secreted by healthy endothelial cells; relaxes vascular smooth muscle and inhibits platelet aggregation.

  • Thrombin Adsorption by Fibrin: As a blood clot forms, the physical fibrin mesh adsorbs up to $90\%$ of local thrombin, preventing it from diffusing downstream into uninjured areas.

  • Antithrombin: Circulating plasma alpha-globulin that binds free thrombin, blocking its catalytic activity on fibrinogen.

  • Heparin: Highly sulfated glycosaminoglycan secreted by circulating basophils and perivascular mast cells; acts as a powerful anticoagulant by increasing antithrombin's inhibitory activity against thrombin and Factor Xa.

Vascular Pathology: Thrombus, Embolism, and Atherosclerosis

• Clinical Definitions:

  • Thrombus: An abnormal, stationary blood clot formed intravascularly within an unbroken blood vessel.

  • Embolus: Any detached intravascular mass, fragment of a dislodged thrombus, or foreign object carried by the bloodstream away from its site of origin.

  • Thrombosis: In situ formation of an obstructive vascular thrombus within an artery supplying a vital organ (such as the brain or myocardium).

  • Embolism: Sudden occlusion of a downstream vessel by an embolus lodging in its lumen (e.g., a pulmonary embolism resulting from a detached deep venous thrombus entering pulmonary arterial branches).

  • Infarction: Coagulative tissue necrosis resulting from prolonged ischemia secondary to complete thrombotic or embolic occlusion of an end-artery.

• Atherosclerosis and Vessel Morphometry:

  • Common form of arteriosclerosis characterized by the subendothelial accumulation of fatty plaques, cholesterol crystals, and smooth muscle proliferation within arterial walls.

  • Histopathological Consequence: Protruding plaques damage the overlying endothelium, creating rough surfaces that promote platelet adhesion and activate the intrinsic clotting cascade.

  • Narrowing of the lumen elevates vascular resistance and disrupts laminar blood flow, increasing the risk of occlusive thrombosis.

Blood Groups and Transfusions: ABO System and Compatibility

• Historical Discovery: In 1910, the identification and genetic characterization of the human ABO blood antigen groups provided an explanation for historically fatal, unexplained post-transfusion reactions.

• Molecular Basis of Blood Groups:

  • Antigens (Agglutinogens): Inherited surface glycoproteins and glycolipids displayed on the outer leaflet of the erythrocyte plasma membrane. In the ABO group, these antigenic determinants consist of branched oligosaccharide chains linked to membrane lipids.

  • Antibodies (Agglutinins): Naturally occurring preformed plasma immunoglobulins directed against foreign ABO oligosaccharide antigens that the individual lacks.

  • Agglutination Reaction: When circulating plasma antibodies bind their corresponding surface antigens on foreign RBCs, the multivalent antibodies cross-link adjacent cells, producing visible clumping.

  • Clinical Transfusion Reaction: Severe systemic reaction caused by agglutination and complement-mediated intravascular hemolysis of donor RBCs. Symptoms include acute anxiety, dyspnea, facial flushing, severe headache, bursting substernal or lumbar pain, acute hemoglobinuria, jaundice, and potential renal failure.

• ABO Group Antigen and Antibody Distribution:

• Universal Donor and Universal Recipient Concepts:

  • Universal Donor (Type O): Type O erythrocytes lack both A and B surface antigens. Consequently, recipient Anti-A and Anti-B antibodies cannot bind the donor cells, minimizing the risk of major hemolytic destruction. When given as whole blood, type O must be administered slowly and in small volumes to allow recipient blood volume to dilute donor antibodies.

  • Universal Recipient (Type AB): Type AB individuals naturally lack both Anti-A and Anti-B antibodies in their plasma. As a result, they can receive transfusions of packed erythrocytes of any ABO blood type without anti-A or anti-B antibodies attacking the donor cells.

• Comprehensive Transfusion Compatibility Protocol:

The Rh Blood Group and Hemolytic Disease of the Newborn (Erythroblastosis Fetalis)

• Antigenic Basis of the Rh Factor:

  • Named after the Rhesus monkey, in which the corresponding surface factors were first investigated.

  • Composed of several surface transmembrane proteins, the most immunogenic of which is Antigen D.

  • Rh-Positive ($\text{Rh}^+$): Indicates the presence of Antigen D (or other key Rh determinants) on erythrocyte membranes.

  • Rh-Negative ($\text{Rh}^-$): Indicates the inherited absence of Antigen D on erythrocyte membranes.

• Anti-Rh Antibody Dynamics:

  • Unlike the ABO system, anti-Rh antibodies do not form spontaneously within the plasma of $\text{Rh}^-$ individuals.

  • Sensitization: Anti-Rh antibodies develop only after an $\text{Rh}^-$ individual is exposed to $\text{Rh}^+$ erythrocytes carrying Antigen D. This occurs via mismatched blood transfusions or fetal-maternal transplacental hemorrhage.

  • Primary Exposure: Elicits a slow, delayed immune response; anti-Rh antibodies require several days to weeks to accumulate in plasma, typically preventing an immediate, severe hemolytic reaction during an initial mismatched transfusion.

  • Secondary Exposure: Sensitized $\text{Rh}^-$ plasma containing high-titer anti-Rh antibodies rapidly binds and hemolyzes transfused $\text{Rh}^+$ cells, triggering an acute hemolytic transfusion reaction.

• Pathogenesis of Erythroblastosis Fetalis (Hemolytic Disease of the Newborn):

  • Gestational Conditions: Occurs when an $\text{Rh}^-$ female carries an $\text{Rh}^+$ fetus (who inherited the dominant D allele from an $\text{Rh}^+$ father).

  • First Gestation: The maternal and fetal circulatory systems remain structurally separated by the placental barrier during gestation, allowing an initial $\text{Rh}^+$ pregnancy to progress without immune complications.

  • Intrapartum Sensitization: Mechanical separation and placental tearing during labor or delivery allow fetal $\text{Rh}^+$ red blood cells carrying Antigen D to enter the maternal bloodstream. Over the weeks and months following delivery, the mother mounts an immune response and produces circulating Anti-Rh (anti-D) IgG antibodies.

  • Subsequent Gestations: If the sensitized $\text{Rh}^-$ mother conceives a second $\text{Rh}^+$ fetus, maternal Anti-Rh IgG antibodies cross the placenta into the fetal circulation, where they bind fetal Antigen D. This triggers severe, complement-mediated erythrocyte hemolysis, leading to profound fetal anemia, hepatosplenomegaly, brain damage (kernicterus), or intrauterine fetal demise.